Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa
Rob Schuster1, Sarah J Lee, Donald Rink
1Department of Surgery, Santa Barbara Cottage Hospital, Santa Barbara, California 93102, USA.
Recombinant factor VIIa (rFVIIa) has been used to treat bleeding complications in patients with hemophilia. It acts at the site of vessel injury, forming a complex with tissue factor to activate the clotting cascade. Recent reports have shown rFVIIa may be a useful hemostatic agent in patients after obstetrical, urologic, trauma, or transplant procedures. We report the first documented case of bleeding from hemorrhage pancreatitis treated with rFVIIa.
Recombinant factor VIIa (rFVIIa) has been used to treat bleeding complications in patients with hemophilia. It acts at the site of vessel injury, forming a complex with tissue factor to activate the clotting cascade. Recent reports have shown rFVIIa may be a useful hemostatic agent in patients after obstetrical, urologic, trauma, or transplant procedures. We report the first documented case of bleeding from hemorrhage pancreatitis treated with rFVIIa.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Chronic Pancreatitis II: Collaborative Care
Assessment:


